TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Jaguar Animal Health ( (JAGX) ) is now available.
On November 17, 2025, Jaguar Health, Inc. announced amendments to its royalty interests with Iliad Research and Trading, Uptown Capital, and Streeterville Capital, setting a minimum monthly royalty payment starting April 1, 2026. Additionally, the company extended the maturity date of a secured promissory note with Streeterville to April 1, 2026. In a separate exchange transaction, Jaguar Health issued common stock to Streeterville in exchange for preferred stock, which was then cancelled.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its poor financial performance, characterized by high leverage and consistent losses. While there is some positive sentiment from recent earnings and clinical advancements, the technical indicators and valuation metrics remain weak, contributing to a low overall score.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Average Trading Volume: 144,946
Technical Sentiment Signal: Sell
Current Market Cap: $6.69M
See more insights into JAGX stock on TipRanks’ Stock Analysis page.